This HTML5 document contains 98 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/chemspider/
n10http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n24http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/wikipedia/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/pharmgkb/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01331/identifier/drugbank/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01331
rdf:type
n3:Drug
n3:description
Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.
n3:dosage
n8:271B3F57-363D-11E5-9242-09173F13E4C5 n8:271B3F58-363D-11E5-9242-09173F13E4C5 n8:271B3F59-363D-11E5-9242-09173F13E4C5 n8:271B3F5A-363D-11E5-9242-09173F13E4C5 n8:271B3F4C-363D-11E5-9242-09173F13E4C5 n8:271B3F4D-363D-11E5-9242-09173F13E4C5 n8:271B3F4E-363D-11E5-9242-09173F13E4C5 n8:271B3F4F-363D-11E5-9242-09173F13E4C5 n8:271B3F50-363D-11E5-9242-09173F13E4C5 n8:271B3F51-363D-11E5-9242-09173F13E4C5 n8:271B3F52-363D-11E5-9242-09173F13E4C5 n8:271B3F53-363D-11E5-9242-09173F13E4C5 n8:271B3F54-363D-11E5-9242-09173F13E4C5 n8:271B3F55-363D-11E5-9242-09173F13E4C5 n8:271B3F56-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The half-life after an intravenous dose is 41 to 59 minutes.
n3:indication
For the treatment of serious infections caused by susceptible strains microorganisms.
owl:sameAs
n10:DB01331 n13:DB01331
dcterms:title
Cefoxitin
adms:identifier
n15:Cefoxitin n19:C06887 n20:D02345 n21:DB01331 n22:209807 n23:389981 n25:441199 n26:46505845 n27:0143-9878-25 n28:PA448856
n3:mechanismOfAction
The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.
n3:packager
n7:271B3F3E-363D-11E5-9242-09173F13E4C5 n7:271B3F41-363D-11E5-9242-09173F13E4C5 n7:271B3F42-363D-11E5-9242-09173F13E4C5 n7:271B3F3F-363D-11E5-9242-09173F13E4C5 n7:271B3F40-363D-11E5-9242-09173F13E4C5 n7:271B3F45-363D-11E5-9242-09173F13E4C5 n7:271B3F46-363D-11E5-9242-09173F13E4C5 n7:271B3F43-363D-11E5-9242-09173F13E4C5 n7:271B3F44-363D-11E5-9242-09173F13E4C5 n7:271B3F3D-363D-11E5-9242-09173F13E4C5 n7:271B3F3B-363D-11E5-9242-09173F13E4C5 n7:271B3F3C-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.
n3:synonym
(6R,7S)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cefoxitine Cefoxitina CFX Cephoxitin Cefoxitinum Rephoxitin Ceftoxitin Cefoxitin
n3:toxicity
The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.
n11:hasAHFSCode
n12:08-12-07-12
n3:synthesisReference
Pandurang Deshpande, Bhausaheb Khadangale, "Process for the preparation of cefoxitin." U.S. Patent US20060252928, issued November 09, 2006.
foaf:page
n6:cefoxitin.html n24:cefoxitin.htm
n3:IUPAC-Name
n4:271B3F5F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F65-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F64-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F61-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F62-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F63-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F5D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F5B-363D-11E5-9242-09173F13E4C5 n4:271B3F5E-363D-11E5-9242-09173F13E4C5 n4:271B3F76-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F5C-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n17:J01DC01
n3:H-Bond-Acceptor-Count
n4:271B3F6B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F6C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F66-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F67-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F69-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F68-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F6A-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
35607-66-0
n3:category
n3:containedIn
n16:271B3F47-363D-11E5-9242-09173F13E4C5 n16:271B3F48-363D-11E5-9242-09173F13E4C5 n16:271B3F4A-363D-11E5-9242-09173F13E4C5 n16:271B3F4B-363D-11E5-9242-09173F13E4C5 n16:271B3F49-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3F71-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F73-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F74-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3F75-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F70-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F6F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F72-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F60-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F6D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F6E-363D-11E5-9242-09173F13E4C5